Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Coxsackievirus and application of coxsackievirus in preparation of anti-tumor drugs

A Coxsackie virus and anti-tumor drug technology, which is applied in the field of anti-tumor drugs, can solve problems such as poor effects, and achieve strong cell lysis, improved anti-tumor effects, and low affinity

Active Publication Date: 2014-08-13
WUHAN BOWEIDE BIOTECH CO LTD
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The problem with coxsackie virus as oncolytic virus therapy is that coxsackie virus is a common virus in digestive tract infection, and those patients who have been infected with certain types of coxsackie virus have virus receptors in their body, if Oncolytic therapy with Coxsackieviruses similar to its antigenic type may be less effective
In addition, many tumors treated with oncolytic virus alone have not completely disappeared. How to promote the spread of oncolytic virus in the tumor and improve its oncolytic efficiency needs to be further explored.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coxsackievirus and application of coxsackievirus in preparation of anti-tumor drugs
  • Coxsackievirus and application of coxsackievirus in preparation of anti-tumor drugs
  • Coxsackievirus and application of coxsackievirus in preparation of anti-tumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Obtain the Coxsackievirus CVB3 mutant strain with recombinant structural protein VP1:

[0059] 1. Viral cDNA, cell lines, vectors and strains:

[0060] Viral cDNA: replace the corresponding base site on the genome cDNA sequence of the wild-type Coxsackievirus group B type 3 Nancy strain, and add a NotI restriction site at its 5' end and a SalI restriction site at its 3' end . Then this genomic cDNA is sent to a gene synthesis company (Jiangsu Jinweizhi Biotechnology Co., Ltd.) for whole gene synthesis

[0061] Cloning vector and enzyme: pVax1 was purchased from Invitrogen Company, NotI enzyme and SalI enzyme were purchased from Dalian Takara Company

[0062] Strains: Stbl3 competent cells were purchased from Invitrogene;

[0063] Hela cells: donated by Professor Martin of the Institute of Gynecological Oncology, Tongji Hospital, Huazhong University of Science and Technology.

[0064] 2. Transfection reagent:

[0065] Transfection reagent: Lipofactamine2000 and corr...

Embodiment 2

[0089] Obtain the Coxsackie virus CVB3 mutant strain of structural protein VP1 / VP2 recombination:

[0090] 1. Viruses, cell lines, vectors and strains:

[0091] Virus: the Coxsackievirus CVB3 variant strain of the structural protein VP1 recombinant obtained in Example 1;

[0092] Vectors, tool enzymes, strains and cell lines: pVax1-SalI was constructed in Example 1, NotI enzyme and SalI enzyme, Stbl3 competent cells, and Hela cells were derived from the same sources as in Example 1.

[0093] 2. Transfection reagent:

[0094] Transfection reagent: Lipofactamine2000 and corresponding transfection reagent Opti-MEM were purchased from Invitrogene;

[0095] 3. Experimental steps:

[0096] Using the method of nucleotide primer-mediated gene site-directed mutagenesis, the Coxsackievirus CVB3 mutant strain obtained in Example 1 with the recombination of the structural protein VP1 is located at the 1180 site of the Coxsackievirus genome in the coding region of the structural protein...

Embodiment 3

[0109] Coxsackie virus CVB3 mutant strain obtained by structural protein VP1 / VP2 / regulatory protein recombination:

[0110] 1. Viral cDNA, cell lines, vectors and strains:

[0111] Viral cDNA: replace the corresponding base site on the genome cDNA sequence of the wild-type Coxsackievirus group B type 3 Nancy strain, and add a NotI restriction site at its 5' end and a SalI restriction site at its 3' end . Then this genomic cDNA was sent to a gene synthesis company (Jiangsu Jinweizhi Biotechnology Co., Ltd.) for whole gene synthesis.

[0112] Cloning vector and enzyme: pVax1 was purchased from Invitrogen Company, NotI enzyme and SalI enzyme were purchased from Dalian Takara Company

[0113] Strains: Stbl3 competent cells were purchased from Invitrogene;

[0114] Hela cells: donated by Professor Martin of the Institute of Gynecological Oncology, Tongji Hospital, Huazhong University of Science and Technology.

[0115] 2. Transfection reagent:

[0116] Transfection reagent: Li...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a coxsackievirus, which is a coxsackievirus group B type 3 mutant strain, wherein the genome site 2690 is adenine, and the genome site 3231 is guanine. The coxsackievirus has significant cytolytic capacity and selection specificity, can be used for preparation of anti-tumor drugs, especially anti-lung cancer drugs, anti-liver cancer drugs, anti-prostate cancer drugs, anti-melanoma drugs, anti-breast cancer drugs, anti-colon cancer drugs and anti-rectal cancer drugs, is used for preparation of anti-tumor drugs, and has characteristics of good anti-tumor effect and high safety.

Description

technical field [0001] The invention belongs to the field of antitumor drugs, and more specifically relates to a coxsackie virus and its application for preparing antitumor drugs. Background technique [0002] Oncolytic virus refers to a virus that can kill, lyse, or hinder the growth of tumor cells. Oncolytic viruses can replicate within tumor cells, leading to tumor cell death, lysis, or arrest of tumor cell growth. Oncolytic viruses can specifically replicate and kill tumor cells in tumor cells, the lethality of viruses on tumor cells, and the tumor regression of tumor patients after infection with viruses. Since 1956, researchers have been trying to use viruses for the treatment of cervical cancer. [0003] Coxsackievirus (CV) is a type of enterovirus in the family Picornaviridae Enterovirus. It often infects the respiratory tract and digestive tract. After infection, it is asymptomatic or has cold symptoms such as fever, sneezing, and coughing. Coxsackie virus is an ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/00A61K35/76A61P35/00C12R1/93
Inventor 蔡立刚曹雪芹慕婷
Owner WUHAN BOWEIDE BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com